论文部分内容阅读
目的：用新型微量稀释法对肿瘤患者术后合并感染超广谱β－内酰胺酶菌株进行检测验证。方法：双纸片法初试微量稀释法验证，对２７株肺炎克雷伯氏菌和３２株大肠埃希氏前进行赵广谱β－内酰胺酶（Ｅｘｔｅｎｄｅｄ－Ｓｐｅｆｃ－ｔｒｕｍ－ｔｕｃｔａｍａｓｅｓ，简称ＥＳＢＬｓ）检测。结果：显示肺炎克雷伯氏菌和大肠埃希氏菌ＥＳＢＬｓ携带率分别为１４．８％（４／２７）和９．４％（３／３２）。结论：微量稀释法是一种新型的验证方法，不但可以测ＥＳＢＬｓ，还可以同时测多种头孢三代类抗生素的ＭＩＣ，具有不易漏检，重复性好，准确，操作简便，终点易于判断的优点。
OBJECTIVE: To test and validate the extended-spectrum β-lactamase-producing strains of tumor patients after infection with novel microdilution method. METHODS: Two-disk method was used to verify the preliminary microdilution method for 27 strains of K.pneumoniae and 32 strains of E. coli. Extended-Spefc-trum-tuctamases (ESBLs) Testing. Results: The ESBLs carrying rates of K. pneumoniae and E. coli were 14.8% (4/27) and 9.4% (3/32), respectively. Conclusion: The microdilution method is a new type of verification method. It not only can measure ESBLs, but also can simultaneously measure the MICs of multiple cephalosporin third-generation antibiotics. It has the advantages of easy missed detection, good repeatability, accuracy, easy operation, and easy to determine the end point. .